(oh-MEH-pray-ZAHL)
Losec
Indicates Canadian trade names.
Action:
Suppresses gastric acid secretion by blocking "acid (proton) pump"
within gastric parietal cell.
Indications:
Short-term treatment of active duodenal ulcer, gastroesophageal reflux disease (GERD), including erosive esophagitis and symptomatic GERD; long-term treatment of pathologic hypersecretory conditions (eg, Zollinger-Ellison syndrome, multiple endocrine adenomas, systemic mastocytosis); to maintain healing of erosive esophagitis; in combination with clarithromycin to eradicate
Contraindications:
Standard considerations.
Active Duodenal Ulcer
Adults:
Erosive Esophagitis
Adults:
Maintenance:
20 mg daily.
Pathologic Hypersecretory Conditions
Route/Dosage:
PO
20 mg/day for 4 to 8 wk.
PO
20 mg/day for 4 to 8 wk.
Adults:
Adults (triple therapy):
Adults (dual therapy):
Gastric ulcer
Adults:
GERD
Adults (without esophageal lesions):
Adults (with erosive esophagitis):
PO
Initial dose: 60 mg/day. Doses up to 120 mg tid have been given. Divide daily doses > 80 mg.
PO
20 mg omeprazole plus clarithromycin 500 mg plus amoxicillin 1000 mg each given bid for 10 days; continue omeprazole 20 mg daily for an additional 18 days if an ulcer is present at start of therapy.
PO
40 mg omeprazole once daily plus clarithromycin 500 mg tid for 14 days;
continue omeprazole 20 mg daily for an additional 14 days if an ulcer is present at start of therapy.
PO
40 mg once daily for 4 to 8 wk.
PO
20 mg daily for 4 wk.
PO
20 mg daily for 4 to 8 wk.
Interactions:
Benzodiazepines: Clearance of benzodiazepines may be decreased.
Clarithromycin: Serum concentrations of clarithromycin and omeprazole may be increased.
Drugs depending on gastric pH for bioavailability (eg, ketoconazole, iron salts, ampicillin): Absorption of these drugs may be affected.
Phenytoin: Decreased plasma clearance and increased half-life phenytoin.
Warfarin: Prolonged warfarin elimination.
Lab Test Interferences:
None well documented.
Adverse Reactions:
Precautions:
Pregnancy: Category C.
Lactation: Undetermined.
Children: Safety and efficacy in children not established.
Administration/Storage:
Assessment/Interventions:
| OVERDOSAGE: SIGNS & SYMPTOMS Confusion, drowsiness, blurred vision, tachycardia, nausea, diaphoresis, flushing, headache, dry mouth |
Patient/Family Education:
AtoZ Drug Facts · Copyright©2000 by Facts and Comparisons